Studie - Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Laboratory), Therapeutic Area (Oncology, Infectious Disease), Molecule Type (Vaccine, CGT), End User (Pharma, Biopharma, Research Institute) - Global Forecast to 2026

MarketsAndMarkets
08.2021
374 Seiten

 
Typ:
Studie
Verfüg­barkeit:
verfügbar
Sprache:
Deutsch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF, versandkostenfrei
PDF, versandkostenfrei
PDF, versandkostenfrei
PDF, versandkostenfrei


"The contract research organization (CRO) services market is projected to reach USD 86.5 billion by 2026 from USD 53.2 billion in 2021, at a CAGR of 10.7% during the forecast period, owing to increasing number of clinical trials, rising prevalence of orphan & rare diseases and high cost of in-house drug development.

“By type, the clinical research services segment accounted for the largest share of the contract research organization (CRO) services market”

The contract research organization (CRO) services market by type is categorized into major early-phase services, clinical research services, laboratory services, and consulting services. Clinical research services segment dominated the market in 2020. The large share of this segment can be attributed to growing demand for newer drugs and subsequent increase in the prevalence of chronic diseases.

“Asia Pacific: The fastest-growing region in the contract research organization (CRO) services market.”

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to implementation of favorable government policies and increasing number of newly established manufacturing facilities.

“North America: the largest share of the contract research organization (CRO) services market”

North America accounted for the largest share of the contract research organization (CRO) services market. Rapid growth in the biosimilar and biologics markets and an increase in clinical trial activity are the major factors driving the market growth.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

By Respondent– Supply Side- 70%, Demand Side- 30%

By Designation— Executives- 25%, CXOs & Directors--30%, Managers - 45%

By Region— North America - 40%, Europe - 25%, APAC – 20%, LATAM- 10%, MEA- 5%

The contract research organization (CRO) services market is dominated by a few globally established players such as including IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), Parexel International (US), PPD (US), and ICON Plc (US). Other players operating in the market are Medpace Holdings (US), SGS (Switzerland), PSI CRO AG (US), Axcent Advanced Analytics (US), BIO Agile Therapeutics (US), Firma Clinical Research (US), Acculab Life Sciences (US), Azelix (US), CTserv (US), Pepgra (UK), and Dove Quality Solutions (US), Novotech Health Holding (Australia), Geneticist Inc. (US), Linical Americas (US), Frontage Holding Corporation (US), and Celerion (US).

Research Coverage:

The report segments the contract research organization (CRO) services market based on region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa),

Type (Early-Phase Services (Chemistry, Manufacturing & Control, Preclinical Services (Pharmacokinetics/Pharmacodynamics (PK/PD), Toxicology Testing, Other Preclinical Services), Discovery Studies), Clinical Research Services (Phase I, Phase II, Phase III, Phase IV), Laboratory Services (Bioanalytical Testing, Analytical Testing, Physical Characterization, Raw Material Testing, Batch Release Testing, Stability Testing, Other Analytical Testing, Consulting Services, and Data Management Services), Therapeutic Area (Oncology, Infectious Diseases, Neurology, Cardiovascular System (CVS) Disorders, Metabolic Disorders/Endocrinology, Immunological Disorders, Respiratory Disorders, Psychiatry, Dermatology, Hematology, Ophthalmology, Gastrointestinal Diseases, Genitourinary & Women’s Health, and Other Therapeutic Areas), End User (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Academic Institutes)

The report also provides a comprehensive review of market drivers, challenges, and opportunities in the contract research organization (CRO) services market.

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the contract research organization (CRO) services market and provides them information on key market drivers, challenges, and opportunities."

"1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.2.1 INCLUSIONS & EXCLUSIONS 49
1.3 MARKET SCOPE 50
FIGURE 1 CRO SERVICES MARKET 50
1.3.1 YEARS CONSIDERED FOR THE STUDY 51
1.4 CURRENCY 51
1.5 LIMITATIONS 51
1.6 STAKEHOLDERS 52
1.7 SUMMARY OF CHANGES 52
2 RESEARCH METHODOLOGY 53
2.1 RESEARCH DATA 53
FIGURE 2 RESEARCH DESIGN 53
2.1.1 SECONDARY DATA 54
2.1.2 PRIMARY DATA 55
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES 55
2.2 MARKET SIZE ESTIMATION 56
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET 56
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020 56
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020 57
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 58
FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2021–2026 59
FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES 59
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 60
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 61
FIGURE 10 DATA TRIANGULATION METHODOLOGY 61
2.5 INSIGHTS FROM PRIMARIES 62
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 62
2.6 RESEARCH ASSUMPTIONS 62
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS 63
2.7 RISK ANALYSIS 63

3 EXECUTIVE SUMMARY 64
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 64
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2021 VS. 2026 (USD MILLION) 65
FIGURE 14 CRO SERVICES MARKET, BY MOLECULE TYPE, 2021 VS. 2026 (USD MILLION) 66
FIGURE 15 CRO SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 66
FIGURE 16 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET 67
4 PREMIUM INSIGHTS 68
4.1 CRO SERVICES MARKET OVERVIEW 68
FIGURE 17 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH 68
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY PRODUCT & COUNTRY (2020) 69
FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CRO SERVICES MARKET IN 2020 69
4.3 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 70
FIGURE 19 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2026 70
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2020 71
FIGURE 20 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2020 71
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN CRO SERVICES MARKET FROM 2021 TO 2026 71
5 MARKET OVERVIEW 72
5.1 INTRODUCTION 72
5.2 MARKET DYNAMICS 72
FIGURE 22 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 72
TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS 73
5.2.1 DRIVERS 73
5.2.1.1 Increasing investment in pharmaceutical R&D 73
FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2016 74
FIGURE 24 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021 75
5.2.1.2 Rising number of clinical trials creates significant demand
for CRO services 75
FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021) 75
5.2.1.3 High cost of in-house drug development encourages pharma biotech companies to outsource contract R&D services 76
FIGURE 26 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 76
5.2.1.4 Rising prevalence of orphan and rare diseases creates new revenue pockets for CROs 77
5.2.2 OPPORTUNITIES 77
5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic 77
FIGURE 27 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020) 78
TABLE 2 LIST OF BIOLOGICS APPROVALS BY US FDA, 2020 78
5.2.2.2 Rising demand for specialized testing services among end users 79
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 79
5.2.3 CHALLENGES 80
5.2.3.1 Shortage of skilled professionals for clinical trials 80
5.2.3.2 Requirement for unique analytical testing approach for innovative formation 80
5.2.4 MARKET TRENDS 80
5.2.4.1 Revolutionary shift in CRO services market due to growing adoption of artificial intelligence-based tools for drug discovery 80
5.2.4.2 Increased outsourcing to emerging Asian economies 81
5.2.4.3 CRO industry consolidation 82
TABLE 3 LIST OF ACQUISITIONS 83
5.2.4.4 Integrated end-to-end R&D service solution 83
5.3 RANGES/SCENARIO 84
FIGURE 28 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF CRO SERVICES MARKET 84
5.4 IMPACT OF COVID-19 OUTBREAK ON CRO SERVICES MARKET 84
FIGURE 29 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021 85
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 86
FIGURE 30 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS 87
5.6 PRICING ANALYSIS 87
TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020) 88
5.7 VALUE CHAIN ANALYSIS 88
FIGURE 31 VALUE CHAIN ANALYSIS OF CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE 89
5.8 ECOSYSTEM ANALYSIS 89
FIGURE 32 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET 90
TABLE 5 SUPPLY CHAIN ECOSYSTEM 90
5.9 TECHNOLOGY ANALYSIS 92
5.10 CASE STUDY 92
5.10.1 COVANCE FSPX DATA ANALYSIS USED TO DETERMINE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIAL 92
5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR 92
5.11 REGULATORY ANALYSIS 93
5.12 PORTER’S FIVE FORCES ANALYSIS 96
TABLE 6 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 96
5.12.1 THREAT OF NEW ENTRANTS 96
5.12.2 THREAT OF SUBSTITUTES 97
5.12.3 BARGAINING POWER OF BUYERS 97
5.12.4 BARGAINING POWER OF SUPPLIERS 97
5.12.5 DEGREE OF COMPETITION 97
6 CRO SERVICES MARKET, BY TYPE 98
6.1 INTRODUCTION 99
TABLE 7 CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 99
6.2 CLINICAL RESEARCH SERVICES 99
6.2.1 GROWING NUMBER OF CLINICAL TRIALS AND PARTNERSHIPS WITH CROS PROPEL GROWTH OF SEGMENT 99
TABLE 8 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF JUNE 2021, BY LOCATION 100
TABLE 9 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS 100
FIGURE 33 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020 102
TABLE 10 CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 102
TABLE 11 CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 102
TABLE 12 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 103
TABLE 13 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 103
TABLE 14 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 103
6.2.2 PHASE III CLINICAL RESEARCH SERVICES 104
6.2.2.1 Rising cost of Phase III trials and high number of patients recruited in these trials increases demand for cost effective CRO services 104
TABLE 15 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY 104
TABLE 16 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 105
TABLE 17 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 18 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 19 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 106
6.2.3 PHASE II CLINICAL RESEARCH SERVICES 106
6.2.3.1 Long duration of Phase II studies provides growth
opportunities for CROs 106
TABLE 20 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES 106
TABLE 21 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 107
TABLE 22 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 107
TABLE 23 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 24 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 108
6.2.4 PHASE I CLINICAL RESEARCH SERVICES 108
6.2.4.1 Robust pipeline of pharmaceutical companies drives segment growth 108
TABLE 25 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES 109
TABLE 26 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 109
TABLE 27 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 28 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 29 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 110
6.2.5 PHASE IV CLINICAL RESEARCH SERVICES 111
6.2.5.1 Rising number of CROs providing post-marketing surveillance drives segment growth 111
TABLE 30 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES 111
TABLE 31 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 112
TABLE 32 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 112
TABLE 33 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 112
TABLE 34 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 113
6.3 EARLY-PHASE DEVELOPMENT SERVICES 113
6.3.1 RISING NEED FOR EARLY-PHASE DEVELOPMENT STUDIES FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH 113
FIGURE 34 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2019) 114
TABLE 35 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS 114
TABLE 36 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 115
TABLE 37 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 115
TABLE 38 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 39 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 40 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 116
6.3.2 CHEMISTRY, MANUFACTURING & CONTROL SERVICES 117
6.3.2.1 High demand for CMC services to check quality standards of drugs 117
TABLE 41 CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 117
TABLE 42 NORTH AMERICA: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 117
TABLE 43 EUROPE: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 118
TABLE 44 ASIA PACIFIC: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 118
6.3.3 PRECLINICAL SERVICES 119
6.3.3.1 Rising demand for preclinical services for PK/PD and toxicology testing propels growth of segment 119
TABLE 45 PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 119
TABLE 46 PRECLINICAL SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 120
TABLE 47 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 120
TABLE 48 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 120
TABLE 49 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 121
6.3.4 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES 121
6.3.4.1 Increasing importance of studies to determine pharmacokinetic behavior of drug candidates to drive segment 121
TABLE 50 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 122
TABLE 51 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 52 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 53 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 123
6.3.5 TOXICOLOGY TESTING SERVICES 123
TABLE 54 TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 124
TABLE 55 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 56 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 124
TABLE 57 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 125
6.3.6 OTHER PRECLINICAL SERVICES 125
6.3.6.1 Increasing use of molecular imaging, flow cytometry, and immunohistochemistry to boost segment 125
TABLE 58 OTHER PRECLINICAL SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 125
TABLE 59 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 60 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 126
TABLE 61 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 126
6.3.7 DISCOVERY STUDIES 127
6.3.7.1 Rising importance of CRO services for target identification and validation to promote segment growth 127
TABLE 62 DISCOVERY STUDIES MARKET, BY REGION, 2019–2026 (USD MILLION) 127
TABLE 63 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 127
TABLE 64 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
TABLE 65 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
6.4 LABORATORY SERVICES 128
6.4.1 INCREASING IMPORTANCE OF LAB SERVICES TO ENSURE REGULATORY COMPLIANCE TO PROPEL SEGMENT GROWTH 128
TABLE 66 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 129
TABLE 67 LAB SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 129
TABLE 68 LAB SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 130
TABLE 69 NORTH AMERICA: LAB SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 130
TABLE 70 EUROPE: LAB SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 130
TABLE 71 ASIA PACIFIC: LAB SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 131
6.4.2 ANALYTICAL TESTING SERVICES 131
6.4.2.1 Increasing demand for analytical testing for all stages of drug development drive growth of segment 131
TABLE 72 ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 73 ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 132
TABLE 74 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 132
TABLE 75 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 132
TABLE 76 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 133
6.4.3 PHYSICAL CHARACTERIZATION 133
6.4.3.1 Increasing demand for physical characterization to reduce risk of product failure drives segment growth 133
TABLE 77 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 134
TABLE 78 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 134
TABLE 79 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 134
TABLE 80 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 135
6.4.4 RAW MATERIAL TESTING 135
6.4.4.1 High demand for testing services to ensure quality and purity of raw materials drives growth of segment 135
TABLE 81 RAW MATERIAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 136
TABLE 82 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 136
TABLE 83 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 136
TABLE 84 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 137
6.4.5 BATCH RELEASE TESTING 137
6.4.5.1 Comprehensive portfolio of batch-release testing services offered by CROs to propel segment growth 137
TABLE 85 BATCH RELEASE TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 138
TABLE 86 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 138
TABLE 87 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 138
TABLE 88 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 139
6.4.6 STABILITY TESTING 139
6.4.6.1 Used to ensure long-term quality, safety, and efficacy of pharmaceutical products 139
TABLE 89 STABILITY TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 140
TABLE 90 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 140
TABLE 91 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 140
TABLE 92 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 141
6.4.7 OTHER ANALYTICAL TESTING 141
6.4.7.1 Demand for analytical method validation, cleaning validation, and microbial testing to propel segment growth 141
TABLE 93 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 141
TABLE 94 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 142
TABLE 95 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 142
TABLE 96 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 142
6.4.8 BIOANALYTICAL TESTING SERVICES 143
6.4.8.1 High demand for bioanalytical testing due to growing use of macromolecules and biosimilars 143
TABLE 97 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 143
TABLE 98 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 143
TABLE 99 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 144
TABLE 100 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 144
6.5 CONSULTING SERVICES 144
6.5.1 INCREASING ADOPTION OF CONSULTING SERVICES FOR QUALITY ASSURANCE PURPOSES PROPELS SEGMENT GROWTH 144
TABLE 101 CONSULTING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 145
TABLE 102 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 145
TABLE 103 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 146
TABLE 104 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 146
6.6 DATA MANAGEMENT SERVICES 146
6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD 146
TABLE 105 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 147
TABLE 106 DATA MANAGEMENT SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 148
TABLE 107 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 148
TABLE 108 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 149
TABLE 109 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 149
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA 150
7.1 INTRODUCTION 151
TABLE 110 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 151
7.2 ONCOLOGY 152
7.2.1 INCREASING NUMBER OF CANCER CASES DRIVES GROWTH OF SEGMENT 152
FIGURE 35 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020) 152
FIGURE 36 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS) 153
TABLE 111 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020) 153
TABLE 112 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION,
2019–2026 (USD MILLION) 154
TABLE 113 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 154
TABLE 114 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 155
TABLE 115 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 155

7.3 INFECTIOUS DISEASES 155
7.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES 155
TABLE 116 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION,
2019–2026 (USD MILLION) 156
TABLE 117 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 156
TABLE 118 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 157
TABLE 119 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 157
7.4 NEUROLOGY 157
7.4.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS DRIVES MARKET 157
TABLE 120 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) 158
TABLE 121 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,
2019–2026 (USD MILLION) 159
TABLE 122 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 159
TABLE 123 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 159
TABLE 124 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 160
7.5 CARDIOVASCULAR SYSTEM DISORDERS 160
7.5.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 160
TABLE 125 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) 161
TABLE 126 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,
BY REGION, 2019–2026 (USD MILLION) 161
TABLE 127 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 162
TABLE 128 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 162
TABLE 129 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 162
7.6 METABOLIC DISORDERS/ENDOCRINOLOGY 163
7.6.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE MARKET GROWTH 163
FIGURE 37 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM
2000 TO 2045 (IN MILLIONS) 163
TABLE 130 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY,
BY REGION, 2019–2026 (USD MILLION) 164
TABLE 131 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 164
TABLE 132 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 164
TABLE 133 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 165
7.7 IMMUNOLOGICAL DISORDERS 165
7.7.1 GROWING IMMUNOLOGIAL DRUGS PIPELINE RESULTING IN INCREASE IN OUTSOURCING ACTIVITIES 165
TABLE 134 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2019–2026 (USD MILLION) 166
TABLE 135 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 166
TABLE 136 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 166
TABLE 137 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 167
7.8 RESPIRATORY DISORDERS 167
7.8.1 INCREASING PREVALENCE OF RESPIRATORY DISEASE TO SUPPORT GROWTH OF SEGMENT 167
TABLE 138 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020) 168
TABLE 139 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2019–2026 (USD MILLION) 169
TABLE 140 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 169
TABLE 141 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 169
TABLE 142 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 170
7.9 PSYCHIATRY 170
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH 170
TABLE 143 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2019–2026 (USD MILLION) 171
TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019–2026 (USD MILLION) 171
TABLE 145 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2019–2026 (USD MILLION) 171
TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019–2026 (USD MILLION) 172
7.10 DERMATOLOGY 172
7.10.1 INCREASING PREVALENCE OF SKIN DISORDERS PROPELS SEGMENT GROWTH 172
TABLE 147 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020) 173
TABLE 148 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION,
2019–2026 (USD MILLION) 173
TABLE 149 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2019–2026 (USD MILLION) 174
TABLE 150 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 174
TABLE 151 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 174

7.11 HEMATOLOGY 175
7.11.1 DEVELOPMENT OF DRUGS FOR HEMATOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 175
TABLE 152 CRO SERVICES MARKET FOR HAEMATOLOGY, BY REGION,
2019–2026 (USD MILLION) 175
TABLE 153 NORTH AMERICA: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 175
TABLE 154 EUROPE: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY,
2019–2026 (USD MILLION) 176
TABLE 155 ASIA PACIFIC: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 176
7.12 OPHTHALMOLOGY 176
7.12.1 GROWING NEED FOR OPTHALMOLOGY-RELATED CLINICAL TRIALS 176
TABLE 156 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,
2019–2026 (USD MILLION) 177
TABLE 157 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2019–2026 (USD MILLION) 177
TABLE 158 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 177
TABLE 159 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 178
7.13 GASTROINTESTINAL DISEASES 178
7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES AND GROWING INVESTMENT IN R&D TO PROPEL MARKET 178
TABLE 160 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2019–2026 (USD MILLION) 179
TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 179
TABLE 162 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 179
TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 180
7.14 GENITOURINARY & WOMEN’S HEALTH 180
7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN DRIVES SEGMENT GROWTH 180
TABLE 164 CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,
BY REGION, 2019–2026 (USD MILLION) 181
TABLE 165 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD MILLION) 181
TABLE 166 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD MILLION) 181
TABLE 167 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD MILLION) 182
7.15 OTHER THERAPEUTIC AREAS 182
7.15.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPPORT SEGMENT GROWTH 182
TABLE 168 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019–2026 (USD MILLION) 183
TABLE 169 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 183
TABLE 170 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2019–2026 (USD MILLION) 183
TABLE 171 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2019–2026 (USD MILLION) 184
8 CRO SERVICES MARKET, BY MOLECULE TYPE 185
8.1 INTRODUCTION 186
TABLE 172 CRO SERVICES MARKET, BY MOLECULE TYPE, 2019–2026 (USD MILLION) 186
8.2 VACCINES 186
8.2.1 RISING FOCUS ON IMMUNIZATION FOR INFECTIOUS DISEASES FUELING MARKET GROWTH 186
TABLE 173 COVID-19 VACICNES IN PIPELINE 187
TABLE 174 CRO SERVICES MARKET FOR VACCINES, BY REGION,
2019–2026 (USD MILLION) 187
8.3 CELL & GENE THERAPY 187
8.3.1 INCREASING FUNDING FOR R&D SUPPORTS MARKET GROWTH 187
8.4 OTHER MOLECULE TYPES 188
9 CRO SERVICES MARKET, BY END USER 190
9.1 INTRODUCTION 191
TABLE 175 CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 191
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 191
9.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINE TO DRIVE MARKET GROWTH 191
FIGURE 38 ANNUAL DRUG APPROVALS BY FDA’S CDER (2009–2018) 192
FIGURE 39 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011–2018 193
TABLE 176 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2019–2026 (USD MILLION) 194
TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2019–2026 (USD MILLION) 194
TABLE 178 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2019–2026 (USD MILLION) 194
TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2019–2026 (USD MILLION) 195
9.3 MEDICAL DEVICE COMPANIES 195
9.3.1 INCREASE IN R&D FOR DEVELOPMENT OF ADVANCED MEDICAL DEVICES FUELING MARKET GROWTH 195
FIGURE 40 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2010–2020) 196
FIGURE 41 R&D EXPENSES OF LEADING MEDICAL DEVICE COMPANIES
(IN USD MILLION), 2020 197
TABLE 180 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2019–2026 (USD MILLION) 197
TABLE 181 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 198
TABLE 182 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY COUNTRY, 2019–2026 (USD MILLION) 198
TABLE 183 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 198
9.4 ACADEMIC INSTITUTES 199
9.4.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT 199
TABLE 184 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION,
2019–2026 (USD MILLION) 200
TABLE 185 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2019–2026 (USD MILLION) 200
TABLE 186 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 200
TABLE 187 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,
BY COUNTRY, 2019–2026 (USD MILLION) 201
10 CRO SERVICES MARKET, BY REGION 202
10.1 INTRODUCTION 203
TABLE 188 CRO SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 203
10.2 NORTH AMERICA 203
FIGURE 42 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT 204
TABLE 189 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 205
TABLE 190 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 205
TABLE 191 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019–2026 (USD MILLION) 205
TABLE 192 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 206
TABLE 193 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 206
TABLE 194 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 206
TABLE 195 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 207
TABLE 196 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 207
TABLE 197 NORTH AMERICA: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 208
10.2.1 US 208
10.2.1.1 Largest CRO services market in North America due to robust clinical trial activities 208
FIGURE 43 US CONTINUES TO DOMINATE DISTRIBUTION OF R&D COMPANIES
BY REGION (2020 VS. 2019) 209
TABLE 198 US: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 209
TABLE 199 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 210
TABLE 200 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 210
TABLE 201 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 210
TABLE 202 US: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 211
TABLE 203 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 211
TABLE 204 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 211
TABLE 205 US: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 212
10.2.2 CANADA 212
10.2.2.1 Increasing number of clinical trials to support market growth 212
TABLE 206 CANADA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 213
TABLE 207 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 213
TABLE 208 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 213
TABLE 209 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 214
TABLE 210 CANADA: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 214
TABLE 211 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 214
TABLE 212 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 215
TABLE 213 CANADA: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 215"
10.3 EUROPE 216
FIGURE 44 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018) 216
TABLE 214 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 217
TABLE 215 EUROPE: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 217
TABLE 216 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 217
TABLE 217 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 218
TABLE 218 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 218
TABLE 219 EUROPE: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 218
TABLE 220 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 219
TABLE 221 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 219
TABLE 222 EUROPE: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 220
10.3.1 GERMANY 220
10.3.1.1 Favorable location for clinical trials due to government support and flexible labor laws 220
TABLE 223 GERMANY: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 221
TABLE 224 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 221
TABLE 225 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 221
TABLE 226 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 222
TABLE 227 GERMANY: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 222
TABLE 228 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 222
TABLE 229 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 223
TABLE 230 GERMANY: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 223
10.3.2 UK 224
10.3.2.1 Investment by pharmaceutical sponsors for drug discovery services to support market growth 224
FIGURE 45 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013–2017 (USD MILLION) 224
TABLE 231 UK: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 225
TABLE 232 UK: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 225
TABLE 233 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 225
TABLE 234 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 226
TABLE 235 UK: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 226
TABLE 236 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 226
TABLE 237 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 227
TABLE 238 UK: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 227
10.3.3 FRANCE 227
10.3.3.1 High number of oncology clinical trials to drive market growth 227
TABLE 239 FRANCE: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 228
TABLE 240 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 228
TABLE 241 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 229
TABLE 242 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 229
TABLE 243 FRANCE: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 229
TABLE 244 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 230
TABLE 245 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 230
TABLE 246 FRANCE: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 231
10.3.4 ITALY 231
10.3.4.1 Low drug approval time and growing number of clinical trials to drive market growth 231
TABLE 247 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY
(JANUARY 2021) 231
TABLE 248 ITALY: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 232
TABLE 249 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 232
TABLE 250 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 232
TABLE 251 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 233
TABLE 252 ITALY: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 233
TABLE 253 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 233
TABLE 254 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 234
TABLE 255 ITALY: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 234
10.3.5 SPAIN 235
10.3.5.1 Short study start-up times and rising R&D expenditure to boost market growth 235
FIGURE 46 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011–2017 235
TABLE 256 SPAIN: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 236
TABLE 257 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 236
TABLE 258 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 236
TABLE 259 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 237
TABLE 260 SPAIN: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 237
TABLE 261 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 237
TABLE 262 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 238
TABLE 263 SPAIN: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 238
10.3.6 REST OF EUROPE 239
TABLE 264 ROE: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 240
TABLE 265 ROE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 240
TABLE 266 ROE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 240
TABLE 267 ROE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 241
TABLE 268 ROE: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 241
TABLE 269 ROE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 241
TABLE 270 ROE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 242
TABLE 271 ROE: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 242
10.4 ASIA PACIFIC 243
FIGURE 47 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT 244
TABLE 272 APAC: CRO SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 245
TABLE 273 APAC: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 245
TABLE 274 APAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 245
TABLE 275 APAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 246
TABLE 276 APAC: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 246
TABLE 277 APAC: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 246
TABLE 278 APAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 247
TABLE 279 APAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 247
TABLE 280 APAC: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 248
10.4.1 CHINA 248
10.4.1.1 Dominates market due to robust pharmaceutical industry and presence of prominent CROs 248
TABLE 281 CHINA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 249
TABLE 282 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 249
TABLE 283 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 249
TABLE 284 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 250
TABLE 285 CHINA: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 250
TABLE 286 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 250
TABLE 287 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 251
TABLE 288 CHINA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 251
10.4.2 JAPAN 251
10.4.2.1 Strong focus on research to drive market growth 251
TABLE 289 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA,
2017 VS. 2019 252
TABLE 290 JAPAN: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 252
TABLE 291 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 253
TABLE 292 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 253
TABLE 293 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 253
TABLE 294 JAPAN: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 254
TABLE 295 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 254
TABLE 296 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 254
TABLE 297 JAPAN: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 255
10.4.3 INDIA 255
10.4.3.1 Growing pharmaceutical industry to drive market growth 255
TABLE 298 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA,
2017 VS. 2019 255
TABLE 299 INDIA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 256
TABLE 300 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 256
TABLE 301 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 256
TABLE 302 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 257
TABLE 303 INDIA: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 257
TABLE 304 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 257
TABLE 305 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 258
TABLE 306 INDIA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 258
10.4.4 AUSTRALIA 259
10.4.4.1 Favorable location for drug discovery due to large number of research institutes 259
TABLE 307 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 259
TABLE 308 AUSTRALIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 259
TABLE 309 AUSTRALIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 260
TABLE 310 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 260
TABLE 311 AUSTRALIA: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 260
TABLE 312 AUSTRALIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 261
TABLE 313 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 261
TABLE 314 AUSTRALIA: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 262
10.4.5 SOUTH KOREA 262
10.4.5.1 Government initiatives and growing R&D activities for drug development to drive market growth 262
TABLE 315 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 263
TABLE 316 SOUTH KOREA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 263
TABLE 317 SOUTH KOREA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 263
TABLE 318 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 264
TABLE 319 SOUTH KOREA: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 264
TABLE 320 SOUTH KOREA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 264
TABLE 321 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 265
TABLE 322 SOUTH KOREA: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 265
10.4.6 REST OF ASIA PACIFIC 266
TABLE 323 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA,
BY THERAPEUTIC AREA, 2017 VS. 2019 266
TABLE 324 ROAPAC: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 266
TABLE 325 ROAPAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 267
TABLE 326 ROAPAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 267
TABLE 327 ROAPAC: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 267
TABLE 328 ROAPAC: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 268
TABLE 329 ROAPAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 268
TABLE 330 ROAPAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 268
TABLE 331 ROAPAC: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 269
10.5 LATIN AMERICA 269
10.5.1 GROWING R&D EXPENDITURE IN PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH 269
TABLE 332 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 270
TABLE 333 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 270
TABLE 334 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 270
TABLE 335 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 271
TABLE 336 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 271
TABLE 337 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 271
TABLE 338 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 272
TABLE 339 LATIN AMERICA: CRO SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 272
10.6 MIDDLE EAST & AFRICA 273
10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH 273
TABLE 340 MEA: CRO SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 273
TABLE 341 MEA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,
2019–2026 (USD MILLION) 274
TABLE 342 MEA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 274
TABLE 343 MEA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 274
TABLE 344 MEA: LABORATORY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 275
TABLE 345 MEA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 275
TABLE 346 MEA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 275
TABLE 347 MEA: CRO SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 276
11 COMPETITIVE LANDSCAPE 277
11.1 INTRODUCTION 277
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 277
FIGURE 48 CRO SERVICES MARKET: STRATEGIES ADOPTED 278
11.3 REVENUE ANALYSIS 279
FIGURE 49 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST THREE YEARS 279
11.4 MARKET SHARE ANALYSIS 280
FIGURE 50 CRO SERVICES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020) 280
11.5 COMPANY EVALUATION QUADRANT 281
FIGURE 51 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX, 2020 282
11.5.1 STARS 283
11.5.2 EMERGING LEADERS 283
11.5.3 PERVASIVE PLAYERS 283
11.5.4 PARTICIPANTS 283
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 284
FIGURE 52 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2020 284
11.6.1 PROGRESSIVE COMPANIES 285
11.6.2 STARTING BLOCKS 285
11.6.3 RESPONSIVE COMPANIES 285
11.6.4 DYNAMIC COMPANIES 285

11.7 COMPETITIVE BENCHMARKING 286
11.7.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES) 286
FIGURE 53 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET 286
11.7.2 COMPANY INDUSTRY FOOTPRINT (20 COMPANIES) 287
TABLE 348 INDUSTRY FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET 287
11.7.3 COMPANY SERVICE OFFERING FOOTPRINT (20 COMPANIES) 288
TABLE 349 SERVICE OFFERING FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET 288
11.7.4 COMPANY REGIONAL FOOTPRINT (20 COMPANIES) 289
TABLE 350 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET 289
11.8 COMPETITIVE SCENARIO AND TRENDS 290
11.8.1 SERVICES LAUNCHES 290
TABLE 351 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2017-NOVEMBER 2020 290
11.8.2 DEALS 291
TABLE 352 CRO SERVICES MARKET: DEALS, JANUARY 2017-NOVEMBER 2020 291
11.8.3 OTHER DEVELOPMENTS 292
TABLE 353 CRO SERVICES MARKET: EXPANSION, JANUARY 2017-NOVEMBER 2020 292
12 COMPANY PROFILES 293
12.1 KEY COMPANIES 293
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 IQVIA 293
TABLE 354 IQVIA: BUSINESS OVERVIEW 293
FIGURE 54 IQVIA: COMPANY SNAPSHOT 294
TABLE 355 IQVIA: SERVICE OFFERINGS 294
TABLE 356 IQVIA: SERVICE LAUNCHES 295
TABLE 357 IQVIA: DEALS 295
TABLE 358 IQVIA: EXPANSION 296
12.1.2 LABCORP 297
TABLE 359 LABCORP: BUSINESS OVERVIEW 297
FIGURE 55 LABCORP: COMPANY SNAPSHOT 298
TABLE 360 LABCORP: SERVICE OFFERINGS 298
TABLE 361 LABCORP: SERVICE LAUNCHES 301
TABLE 362 LABCORP: DEALS 301
TABLE 363 LABCORP: EXPANSION 303
12.1.3 SYNEOS HEALTH INC. 304
TABLE 364 SYNEOS HEALTH INC.: BUSINESS OVERVIEW 304
FIGURE 56 SYNEOS HEALTH INC.: COMPANY SNAPSHOT 304
TABLE 365 SYNEOS HEALTH INC.: SERVICE OFFERINGS 305
TABLE 366 SYNEOS HEALTH INC: SERVICE LAUNCHES 307
TABLE 367 SYNEOS HEALTH INC.: DEALS 307
12.1.4 WUXI APPTEC 311
TABLE 368 WUXI APPTEC: BUSINESS OVERVIEW 311
FIGURE 57 WUXI APPTEC: COMPANY SNAPSHOT 312
TABLE 369 WUXI APPTEC : SERVICE OFFERINGS 312
TABLE 370 WUXI APPTEC: SERVICE LAUNCHES 314
TABLE 371 WUXI APPTEC: DEALS 314
TABLE 372 WUXI APPTEC: EXPANSION 316
12.1.5 CHARLES RIVER LABORATORIES 318
TABLE 373 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 318
FIGURE 58 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 319
TABLE 374 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS 319
TABLE 375 CHARLES RIVER LABORATORIES: DEALS 320
TABLE 376 CHARLES RIVER LABORATORIES: EXPANSION 322
12.1.6 PAREXEL INTERNATIONAL 324
TABLE 377 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW 324
TABLE 378 PAREXEL INTERNATIONAL: SERVICE OFFERINGS 325
TABLE 379 PAREXEL INTERNATIONAL: SERVICE LAUNCHES 327
TABLE 380 PAREXEL INTERNATIONAL: DEALS 328
TABLE 381 PAREXEL INTERNATIONAL: EXPANSION 331
12.1.7 PRA HEALTH SCIENCES 332
TABLE 382 PRA HEALTH SCIENCES: BUSINESS OVERVIEW 332
FIGURE 59 PRA HEALTH SCIENCES: COMPANY SNAPSHOT 333
TABLE 383 PRA HEALTH SCIENCES: SERVICE OFFERINGS 333
TABLE 384 PRA HEALTH SCIENCES: SERVICE LAUNCHES 334
TABLE 385 PRA HEALTH SCIENCES: DEALS 335
TABLE 386 PRA HEALTH SCIENCES: EXPANSION 336
12.1.8 PPD INC 337
TABLE 387 PPD INC: BUSINESS OVERVIEW 337
FIGURE 60 PPD INC: COMPANY SNAPSHOT 338
TABLE 388 PPD INC: SERVICE OFFERINGS 338
TABLE 389 PPD: SERVICE LAUNCHES 341
TABLE 390 PPD: DEALS 342
TABLE 391 PPD: EXPANSION 344
12.1.9 ICON PLC 345
TABLE 392 ICON PLC: BUSINESS OVERVIEW 345
FIGURE 61 ICON PLC: COMPANY SNAPSHOT 346
TABLE 393 ICON PLC: SERVICE OFFERINGS 346
TABLE 394 ICON PLC : SERVICE LAUNCHES 349
TABLE 395 ICON PLC: DEALS 350
12.1.10 MEDPACE HOLDINGS INC 351
TABLE 396 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW 351
FIGURE 62 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT 351
TABLE 397 MEDPACE HOLDINGS INC: SERVICE OFFERINGS 352
TABLE 398 MEDPACE HOLDINGS INC: DEALS 353
TABLE 399 MEDPACE HOLDINGS INC: EXPANSION 353
12.1.11 SGS 354
TABLE 400 SGS: BUSINESS OVERVIEW 354
FIGURE 63 SGS: COMPANY SNAPSHOT 355
TABLE 401 SGS: SERVICE OFFERINGS 355
TABLE 402 SGS: DEALS 357
12.1.12 FRONTAGE HOLDINGS CORPORATION 358
TABLE 403 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW 358
FIGURE 64 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT 359
TABLE 404 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS 359
TABLE 405 FRONTAGE HOLDINGS CORPORATION: DEALS 360
TABLE 406 FRONTAGE HOLDINGS CORPORATION: EXPANSION 361
12.1.13 PSI CRO AG 362
TABLE 407 PSI CRO AG: BUSINESS OVERVIEW 362
TABLE 408 PSI CRO AG: SERVICE OFFERINGS 362
TABLE 409 PSI CRO AG: EXPANSION 363
12.1.14 BIO AGILE THERAPEUTICS 364
TABLE 410 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW 364
TABLE 411 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS 364
12.1.15 FIRMA CLINICAL RESEARCH 366
TABLE 412 FIRMA CLINICAL RESEARCH: BUSINESS OVERVIEW 366
TABLE 413 FIRMA CLINICAL RESEARCH: SERVICE OFFERINGS 366
12.1.16 ACCULAB LIFE SCIENCES 367
TABLE 414 ACCULAB LIFE SCIENCES: BUSINESS OVERVIEW 367
TABLE 415 ACCULAB LIFE SCIENCES: SERVICE OFFERINGS 367
12.1.17 NOVOTECH HEALTH HOLDINGS 368
TABLE 416 NOVOTECH HEALTH HOLDINGS: BUSINESS OVERVIEW 368
TABLE 417 NOVOTECH HEALTH HOLDINGS: SERVICE OFFERINGS 368
TABLE 418 NOVOTECH HEALTH HOLDINGS: DEALS 369
12.1.18 GENETICIST INC. 370
TABLE 419 GENETICIST INC.: BUSINESS OVERVIEW 370
TABLE 420 GENETICIST INC.: SERVICE OFFERINGS 370
12.1.19 LINICAL AMERICAS 372
TABLE 421 LINICAL AMERICAS: BUSINESS OVERVIEW 372
TABLE 422 LINICAL AMERICAS: SERVICE OFFERINGS 372
TABLE 423 LINICAL AMERICAS: DEALS 373
12.1.20 CELERION 374
TABLE 424 CELERION.: BUSINESS OVERVIEW 374
TABLE 425 CELERION.: SERVICE OFFERINGS 374
TABLE 426 CELERION.: SERVICE LAUNCHES 375
12.2 OTHER PLAYERS 376
12.2.1 AZELIX 376
TABLE 427 AZELIX: COMPANY OVERVIEW 376
12.2.2 CTSERV 377
TABLE 428 CTSERV: COMPANY OVERVIEW 377
12.2.3 PEPGRA 377
TABLE 429 PEPGRA: COMPANY OVERVIEW 377
12.2.4 AXCENT ADVANCED ANALYTICS (A3) 378
TABLE 430 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW 378
12.2.5 DOVE QUALITY SOLUTIONS 380
TABLE 431 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW 380
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 381
13.1 DISCUSSION GUIDE 381
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 385
13.3 AVAILABLE CUSTOMIZATIONS 387
13.4 RELATED REPORTS 388
13.5 AUTHOR DETAILS 389

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch die zum jeweiligen Zeitpunkt in Deutschland gesetzlich vorgeschriebene Umsatzsteuer (Normalsatz 19%; im Zeitraum vom 01.07.2020 bis zum 31.12.2020 16%) zu entrichten. Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter xing linkedin